- ViewRay ( NASDAQ: VRAY ) said its MRIdian MRI-Guided Radiation Therapy system was approved by China's National Medical Products Administration (NMPA).
- The approval offers cancer patients a new radiation therapy option, MRIdian Stereotactic MRI-Guided Adaptive Radiotherapy (SMART), allowing treatment which integrates diagnostic-quality MR imaging, real-time, soft tissue tracking and automated beam gating, the company said in a Sept. 7 press release.
- VRAY +2.15% to $3.32 premarket Sept. 7
For further details see:
ViewRay's MRI-guided radiation therapy gets approval in China